1
|
Meeder E, Matzaraki V, Vadaq N, van de Wijer L, van der Ven A, Schellekens A. Unbiased Metabolomics Links Fatty Acid Pathways to Psychiatric Symptoms in People Living with HIV. J Clin Med 2021; 10:jcm10235466. [PMID: 34884168 PMCID: PMC8658345 DOI: 10.3390/jcm10235466] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2021] [Revised: 11/18/2021] [Accepted: 11/19/2021] [Indexed: 12/14/2022] Open
Abstract
Psychiatric symptoms are prevalent in people living with HIV (PLWH), especially depression, anxiety, impulsivity, and substance use. Various biological mechanisms might play a role in the occurrence of psychiatric symptoms in this population. A hypothesis free, data-driven metabolomics approach can further our understanding of these mechanisms. In this study, we identified metabolic pathways associated with impulsivity, depression and substance use in 157 PLWH. First, Spearman’s rank correlations between metabolite feature intensities and psychiatric symptom levels were calculated, while controlling for age, gender and body mass index. Subsequently, a mummichog pathway analysis was performed. Finally, we analyzed which individual metabolites drove the observed effects. In our cohort of PLWH, fatty acid-related pathways were associated with both depressive as well as impulsive symptomatology. Substance use showed most extensive metabolic associations, and was positively associated with short chain fatty acids (SCFA’s), and negatively associated with glutamate levels. These findings suggest that PUFA metabolism might be associated with both internalising and externalising symptomatology in PLWH. Furthermore, glutamate and SCFA’s—microbiome derivatives with known neuroactive properties—might be involved in substance use in these patients. Future studies should explore potential causal mechanisms involved and whether these findings are HIV-specific.
Collapse
Affiliation(s)
- Elise Meeder
- Department of Psychiatry, Radboud University Medical Centre, 6525 GA Nijmegen, The Netherlands;
- Nijmegen Institute for Scientist-Practitioners in Addiction (NISPA), Radboud University, 6500 HE Nijmegen, The Netherlands
- Donders Institute for Brain, Cognition and Behavior, Radboud University, 6525 AJ Nijmegen, The Netherlands
- Correspondence: ; Tel.: +31-648-021-927
| | - Vasiliki Matzaraki
- Department of General Internal Medicine, Radboud University Medical Centre, 6525 GA Nijmegen, The Netherlands; (V.M.); (N.V.); (L.v.d.W.); (A.v.d.V.)
| | - Nadira Vadaq
- Department of General Internal Medicine, Radboud University Medical Centre, 6525 GA Nijmegen, The Netherlands; (V.M.); (N.V.); (L.v.d.W.); (A.v.d.V.)
- Center for Tropical and Infectious Diseases (CENTRID), Faculty of Medicine, Diponegoro University, Dr. Kariadi Hospital, Semarang 1269, Indonesia
| | - Lisa van de Wijer
- Department of General Internal Medicine, Radboud University Medical Centre, 6525 GA Nijmegen, The Netherlands; (V.M.); (N.V.); (L.v.d.W.); (A.v.d.V.)
| | - André van der Ven
- Department of General Internal Medicine, Radboud University Medical Centre, 6525 GA Nijmegen, The Netherlands; (V.M.); (N.V.); (L.v.d.W.); (A.v.d.V.)
| | - Arnt Schellekens
- Department of Psychiatry, Radboud University Medical Centre, 6525 GA Nijmegen, The Netherlands;
- Nijmegen Institute for Scientist-Practitioners in Addiction (NISPA), Radboud University, 6500 HE Nijmegen, The Netherlands
- Donders Institute for Brain, Cognition and Behavior, Radboud University, 6525 AJ Nijmegen, The Netherlands
| |
Collapse
|
2
|
Oudejans S, de Weert-van Oene G, Spits M, de Wildt W, Merkx M, Dekker J, Visch I, Goudriaan A. A Self-Reported Version of the Measurements in the Addictions for Triage and Evaluation-Q: Concurrent Validity with the MATE 2.1. Eur Addict Res 2020; 26:20-27. [PMID: 31639811 PMCID: PMC6979419 DOI: 10.1159/000503625] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/30/2019] [Accepted: 09/20/2019] [Indexed: 11/19/2022]
Abstract
INTRODUCTION Substance abuse treatment centers require reliable and valid instruments to monitor treatment progress, to evaluate treatment effectiveness, and to initiate clinical trials. Currently the Measurements in the Addictions for Triage and Evaluation (MATE) 2.1, an instrument that serves these purposes, is considered quite lengthy and intensive, especially in the case of allocation to milder treatment intensity. Therefore, a self-reported version of the MATE-Q was designed for patients with mild to moderate substance-abuse and co-occurring problems. The aim of the present study was to assess concurrent validity with the interviewer version of the MATE (version 2.1). MATERIALS AND METHODS Data were collected at 2 locations of a Dutch substance abuse treatment center, one location in a large city and one in a suburban area. A correlational design was employed, where each included participant completed a MATE-Q and a MATE 2.1 within 3 days or less (administered at intake, before treatment initiation). A total of 98 treatment-seeking patients were included (51.0% alcohol as a primary problem, 19.4% cannabis, 14.3% gambling and 6.1% cocaine). Measurements included the MATE-Q and the MATE 2.1. Intraclass correlation coefficients (ICCs) for single measures were calculated, deploying the 2-way mixed procedure with absolute agreement. Descriptives of scores comprise means and Cronbach's alpha for internal consistency. RESULTS For the majority (15 out of 24) of the scores ICCs were equal or above 0.7. For 93 patients (95%), the primary problem substance or problem behavior was reported correspondingly. Nine MATE-Q mean scores differed significantly from their MATE 2.1 counterparts. DISCUSSION/CONCLUSION For the majority of scores, the MATE-Q has acceptable concurrent validity for the assessment of patients with mild to moderate substance abuse and co-occurring problems.
Collapse
Affiliation(s)
- Suzan Oudejans
- aMark Bench, Amsterdam, The Netherlands,bAmsterdam UMC Department of Psychiatry, Amsterdam Institute for Addiction Research, Amsterdam, The Netherlands,fPhrenos Center of Expertise, Utrecht, The Netherlands,*Suzan Oudejans, Mark Bench, Rhôneweg 16, NL–1043AH Amsterdam (The Netherlands), E-Mail
| | - Gerdien de Weert-van Oene
- dArkin Mental Healthcare Services, Amsterdam, The Netherlands,gNovadic-Kentron, Network for Addiction Treatment, Vught, The Netherlands
| | - Masha Spits
- aMark Bench, Amsterdam, The Netherlands,bAmsterdam UMC Department of Psychiatry, Amsterdam Institute for Addiction Research, Amsterdam, The Netherlands,eDutch Addiction Association, Amersfoort, The Netherlands
| | - Wencke de Wildt
- cJellinek Substance Abuse Treatment Center, Amsterdam, The Netherlands,dArkin Mental Healthcare Services, Amsterdam, The Netherlands
| | - Maarten Merkx
- bAmsterdam UMC Department of Psychiatry, Amsterdam Institute for Addiction Research, Amsterdam, The Netherlands,hHSK, Arnhem, The Netherlands
| | - Jack Dekker
- dArkin Mental Healthcare Services, Amsterdam, The Netherlands,iVrije Universiteit, Faculty of Behavioral and Movement Science, Amsterdam, The Netherlands
| | - Irene Visch
- dArkin Mental Healthcare Services, Amsterdam, The Netherlands
| | - Anneke Goudriaan
- bAmsterdam UMC Department of Psychiatry, Amsterdam Institute for Addiction Research, Amsterdam, The Netherlands,dArkin Mental Healthcare Services, Amsterdam, The Netherlands
| |
Collapse
|